Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PD-1 Blockade Plus Chemotherapy for Locally Advanced Esophageal Carcinoma
NCT05777707Phase 2Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in esophageal carcinoma, sponsored by Beijing Friendship Hospital. Primary endpoint: Disease-free survival at 24 months. Status: unknown.
02
Conditions
esophageal carcinoma
Beyond the preview
Go deeper on NCT05777707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05777707.